Leerink Partnrs Comments on XOMA Co.’s Q1 2024 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA) – Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of XOMA in a research note issued on Monday, April 29th. Leerink Partnrs analyst D. Risinger expects that the biotechnology company will post earnings per share of ($0.85) for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.73) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2024 earnings at ($0.79) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.69) EPS, FY2024 earnings at ($2.87) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $3.31 EPS.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.13). The firm had revenue of $1.83 million for the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%.

Several other brokerages have also weighed in on XOMA. HC Wainwright reissued a “buy” rating and issued a $74.00 price objective on shares of XOMA in a research report on Wednesday. SVB Leerink started coverage on XOMA in a research note on Monday. They issued an “outperform” rating and a $40.00 price target for the company.

XOMA Price Performance

NASDAQ:XOMA opened at $25.82 on Thursday. The stock’s 50 day moving average price is $25.06 and its two-hundred day moving average price is $20.68. XOMA has a 12-month low of $13.48 and a 12-month high of $27.00. The firm has a market capitalization of $300.54 million, a price-to-earnings ratio of -6.39 and a beta of 0.57. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34.

Institutional Inflows and Outflows

An institutional investor recently raised its position in XOMA stock. Stonepine Capital Management LLC boosted its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 25.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 436,602 shares of the biotechnology company’s stock after acquiring an additional 87,203 shares during the quarter. XOMA accounts for about 2.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 12th largest position. Stonepine Capital Management LLC owned 3.80% of XOMA worth $6,152,000 at the end of the most recent quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.